The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled “Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.
The Global Retinal Disease Therapeutics Market is consolidated in nature, with only a handful of market players accounting for the maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success. Therefore the global market is boosted by-products and concepts introduced by existing companies.
Some of the Main Key Players Covered in the Report
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical
North America to Emerge Dominant in the Forecast Period
The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years. The Retinal Disease Therapeutics Market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years.
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311
Improved health infrastructures, increasing patient pool, and favorable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. High prevalence of retinal diseases in the Asia Pacific is a major reason why this region is estimated to rise with the highest CAGR in the forecast period.
By Disease Indication
- Macular Degeneration
- Diabetic Retinopathy
- Diabetic Macular Edema
- Retinal Vein Occlusion
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- Hoffmann-La Roche AG’s ‘Lucentis’ is Gaining Increasing Popularity
The diabetic retinopathy is a severe kind of disorder that has accounted for the majority of cases of blindness in the US. Lucentis was an instant hit among healthcare professionals after it was backed by a series of clinical trials and approvals from the National Institute of Health (NIH).
One such instance of this development is the “Lucentis” therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced to provide therapeutic advice and development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy.
Excellent clinical effects of Lucentis have led to a subsequent rise in demand for medicine among patients. The increasing demand has contributed to the growth of the global retinal disease therapeutics market and is likely to favor the market in the forthcoming years.
More Trending Topics from Fortune Business Insights:
Cosmetic Dentistry Market Set to Show a Drastic Surge with the Demand till 2026 | Key Players: 3M, ALIGN TECHNOLOGY, INC., Zimmer Biomet, Straumann AG. & More
Dialysis Equipment Market Size, Share, Trends 2025 | Leading Players: Fresenius Medical Care, Baxter, B Braun Melsungen, Nipro Corporation, Nikkiso Co., Ltd. & More
Autism Spectrum Disorder Therapeutics Market Size, Growth, Analysis, Insights and Forecast 2019-2026
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]